Table 3.

End Points That Reflect Disease Control

End Point	Trabectedin (n = 345)	Dacarbazine (n = 173)	HR/OR (95% CI)*	P
PFS, months	4.2	1.5	0.55 (0.44 to 0.70)	< .001
TTP, months	4.2	1.5	0.52 (0.41 to 0.66)	< .001
No. (%) of ORR	34 (9.9)	12 (6.9)	1.47 (0.72 to 3.2)	.33
DOR, months	6.5	4.2	0.47 (0.17 to 1.32)	.14
No. (%) with SD as best response	177 (51)	60 (35)	—	—
Duration of SD, months	6.01	4.17	0.45 (0.30 to 0.67)	< .001
% of CBR	34	19	2.3 (1.45 to 3.7)	< .001

Abbreviations: CBR, clinical benefit rate; DOR, duration of response; HR, hazard ratio; OR, odds ratio; ORR, objective response rate; PFS, progression-free survival; SD, stable disease; TTP, time to progression..

^*The HR was calculated as the hazard in the trabectedin treatment group, divided by the hazard in the dacarbazine treatment group.